Literature DB >> 14730621

Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes.

Danielle B Ulanet1, Nicholas A Flavahan, Livia Casciola-Rosen, Antony Rosen.   

Abstract

OBJECTIVE: To investigate the association of specific autoantibodies with distinct disease phenotypes. The association of autoantibodies to nucleophosmin/B23 with pulmonary hypertension in scleroderma, and the susceptibility of autoantigens to cleavage by granzyme B (GB), provided a focus for these studies.
METHODS: Intact cells were subjected to cytotoxic lymphocyte granule-induced death, and the susceptibility of autoantigens to cleavage by GB was addressed by immunoblotting and/or by a novel immunofluorescence assay.
RESULTS: B23 was cleaved efficiently by GB in vitro, but was highly resistant to cleavage by GB during cytotoxic lymphocyte granule-mediated death of many intact cell types. In contrast, this molecule was highly susceptible to GB-mediated proteolysis exclusively in differentiated vascular smooth muscle cells. Topoisomerase I and several other GB substrates did not show this striking change in cleavage susceptibility in different cell types.
CONCLUSION: These data demonstrate that the cleavage of B23 by GB in intact cells is dependent upon both cell type and phenotype. The susceptibility of this autoantigen (which is associated with a distinct pulmonary vascular phenotype in scleroderma) to GB-mediated proteolysis selectively in vascular smooth muscle cells suggests that the GB-cleavable conformation of autoantigens may occur selectively in the target tissue, and may play a role in shaping the phenotype-specific autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730621     DOI: 10.1002/art.11485

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

2.  Granzyme B-induced and caspase 3-dependent cleavage of gelsolin by mouse cytotoxic T cells modifies cytoskeleton dynamics.

Authors:  Praxedis Martin; Julián Pardo; Natalie Schill; Lars Jöckel; Matthias Berg; Christopher J Froelich; Reinhard Wallich; Markus M Simon
Journal:  J Biol Chem       Date:  2010-04-15       Impact factor: 5.157

Review 3.  Apoptosis and autoimmunity.

Authors:  Jeannine S Navratil; Chau-Ching Liu; Joseph M Ahearn
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Granzyme B cleavage of autoantigens in autoimmunity.

Authors:  E Darrah; A Rosen
Journal:  Cell Death Differ       Date:  2010-01-15       Impact factor: 15.828

5.  Granzyme B Induces IRF-3 Phosphorylation through a Perforin-Independent Proteolysis-Dependent Signaling Cascade without Inducing Cell Death.

Authors:  Eric J Gapud; Maria Isabel Trejo-Zambrano; Eduardo Gomez-Banuelos; Eleni Tiniakou; Brendan Antiochos; David J Granville; Felipe Andrade; Livia Casciola-Rosen; Antony Rosen
Journal:  J Immunol       Date:  2020-12-07       Impact factor: 5.422

6.  Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy.

Authors:  Livia Casciola-Rosen; Kanneboyina Nagaraju; Paul Plotz; Kondi Wang; Stuart Levine; Edward Gabrielson; Andrea Corse; Antony Rosen
Journal:  J Exp Med       Date:  2005-02-21       Impact factor: 14.307

7.  Dynamic conformations of nucleophosmin (NPM1) at a key monomer-monomer interface affect oligomer stability and interactions with granzyme B.

Authors:  Wei D Duan-Porter; Virgil L Woods; Kimberly D Maurer; Sheng Li; Antony Rosen
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

Review 8.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.